168 related articles for article (PubMed ID: 36776300)
1. Case report: Successful use of mepolizumab for immune checkpoint inhibitors-induced hypereosinophilic syndrome in two patients with solid malignancies.
Lazzari C; Yacoub MR; Campochiaro C; Bulotta A; Palumbo D; Ogliari FR; Dagna L; Marchesi S; Ponzoni M; Gregorc V
Front Oncol; 2023; 13():1079034. PubMed ID: 36776300
[TBL] [Abstract][Full Text] [Related]
2. Current strategies in the management of hypereosinophilic syndrome, including mepolizumab.
Schwartz LB; Sheikh J; Singh A
Curr Med Res Opin; 2010 Aug; 26(8):1933-46. PubMed ID: 20565230
[TBL] [Abstract][Full Text] [Related]
3. Mepolizumab Reduces Hypereosinophilic Syndrome Flares Irrespective of Blood Eosinophil Count and Interleukin-5.
Rothenberg ME; Roufosse F; Faguer S; Gleich GJ; Steinfeld J; Yancey SW; Mavropoulou E; Kwon N;
J Allergy Clin Immunol Pract; 2022 Sep; 10(9):2367-2374.e3. PubMed ID: 35568330
[TBL] [Abstract][Full Text] [Related]
4. Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome.
Roufosse F; de Lavareille A; Schandené L; Cogan E; Georgelas A; Wagner L; Xi L; Raffeld M; Goldman M; Gleich GJ; Klion A
J Allergy Clin Immunol; 2010 Oct; 126(4):828-835.e3. PubMed ID: 20810155
[TBL] [Abstract][Full Text] [Related]
5. Mepolizumab therapy improves the most bothersome symptoms in patients with hypereosinophilic syndrome.
Roufosse F; Butterfield J; Steinfeld J; Bentley JH; von Maltzahn R; Kwon N; Nelsen L
Front Med (Lausanne); 2023; 10():1035250. PubMed ID: 37064032
[TBL] [Abstract][Full Text] [Related]
6. Association Between Baseline Therapy and Flare Reduction in Mepolizumab-Treated Patients With Hypereosinophilic Syndrome.
Reiter A; Lefevre G; Cid MC; Kwon N; Mavropolou E; Yancey SW; Steinfeld J
Front Immunol; 2022; 13():840974. PubMed ID: 35493455
[TBL] [Abstract][Full Text] [Related]
7. Biologic Agents for the Treatment of Hypereosinophilic Syndromes.
Kuang FL; Klion AD
J Allergy Clin Immunol Pract; 2017; 5(6):1502-1509. PubMed ID: 29122152
[TBL] [Abstract][Full Text] [Related]
8. Characterization of disease flares and impact of mepolizumab in patients with hypereosinophilic syndrome.
Pane F; Lefevre G; Kwon N; Bentley JH; Yancey SW; Steinfeld J
Front Immunol; 2022; 13():935996. PubMed ID: 36091012
[TBL] [Abstract][Full Text] [Related]
9. Severe hypereosinophilic syndrome successfully treated with a monoclonal antibody against interleukin 5 receptor α - benralizumab.
Kosałka-Węgiel J; Milewski M; Siwiec A; Strach M; Ochrem B; Korkosz M
Cent Eur J Immunol; 2021; 46(3):395-397. PubMed ID: 34764813
[TBL] [Abstract][Full Text] [Related]
10. Mepolizumab: 240563, anti-IL-5 monoclonal antibody - GlaxoSmithKline, anti-interleukin-5 monoclonal antibody - GlaxoSmithKline, SB 240563.
Drugs R D; 2008; 9(2):125-30. PubMed ID: 18298130
[TBL] [Abstract][Full Text] [Related]
11. Treatment of patients with the hypereosinophilic syndrome with mepolizumab.
Rothenberg ME; Klion AD; Roufosse FE; Kahn JE; Weller PF; Simon HU; Schwartz LB; Rosenwasser LJ; Ring J; Griffin EF; Haig AE; Frewer PI; Parkin JM; Gleich GJ;
N Engl J Med; 2008 Mar; 358(12):1215-28. PubMed ID: 18344568
[TBL] [Abstract][Full Text] [Related]
12. Hypereosinophilic syndromes.
Roufosse FE; Goldman M; Cogan E
Orphanet J Rare Dis; 2007 Sep; 2():37. PubMed ID: 17848188
[TBL] [Abstract][Full Text] [Related]
13. Treatment of lymphocyte-variant hypereosinophilic syndrome (L-HES): what to consider after confirming the elusive diagnosis.
Williams AK; Dou C; Chen LYC
Br J Haematol; 2021 Dec; 195(5):669-680. PubMed ID: 34105142
[TBL] [Abstract][Full Text] [Related]
14. alpha-Interferon treatment for idiopathic hypereosinophilic syndrome.
Bockenstedt PL; Santinga JT; Bolling SF
Am J Hematol; 1994 Mar; 45(3):248-51. PubMed ID: 8296798
[TBL] [Abstract][Full Text] [Related]
15. Hypereosinophilic syndrome: an update.
Wilkins HJ; Crane MM; Copeland K; Williams WV
Am J Hematol; 2005 Oct; 80(2):148-57. PubMed ID: 16184589
[TBL] [Abstract][Full Text] [Related]
16. Safety and Efficacy of Mepolizumab in Hypereosinophilic Syndrome: An Open-Label Extension Study.
Gleich GJ; Roufosse F; Chupp G; Faguer S; Walz B; Reiter A; Yancey SW; Bentley JH; Steinfeld J;
J Allergy Clin Immunol Pract; 2021 Dec; 9(12):4431-4440.e1. PubMed ID: 34389506
[TBL] [Abstract][Full Text] [Related]
17. [Hypereosinophilic syndromes].
Groh M; Lefèvre G; Ackermann F; Étienne N; Kahn JE
Rev Prat; 2019 Sep; 69(7):767-773. PubMed ID: 32233322
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic and therapeutic management in patients with hypereosinophilic syndromes.
Helbig G; Kyrcz-Krzemień S
Pol Arch Med Wewn; 2011; 121(1-2):44-52. PubMed ID: 21346698
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and pharmacodynamics of mepolizumab, an anti-interleukin-5 monoclonal antibody.
Smith DA; Minthorn EA; Beerahee M
Clin Pharmacokinet; 2011 Apr; 50(4):215-27. PubMed ID: 21348536
[TBL] [Abstract][Full Text] [Related]
20. Eosinophilic cystitis presented as a manifestation of hypereosinophilic syndrome: a case report and review of the literature.
Kojima K; Maeda J; Mikami S; Yamagishi H; Ide H; Hattori S; Takahashi T; Awazu M
Nephron Extra; 2013 Jan; 3(1):30-5. PubMed ID: 23573073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
